{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T20:37:18Z","timestamp":1782938238211,"version":"3.54.5"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,1]]},"DOI":"10.7759\/cureus.111915","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T19:18:56Z","timestamp":1782933536000},"source":"Crossref","is-referenced-by-count":0,"title":["Glucagon-Like Peptide-1 Receptor Agonists and Reproductive Health: A Narrative Review for Obstetrician-Gynecologists"],"prefix":"10.7759","author":[{"given":"Sara","family":"Almaradweh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emad","family":"Mousa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1097\/GCO.0000000000001116","article-title":"What obgyns need to know about GLP-1 receptor agonists","author":"Chauhan I","year":"2026","unstructured":"Chauhan I. What obgyns need to know about GLP-1 receptor agonists. Curr Opin Obstet Gynecol. 2026, 10.1097\/GCO.0000000000001116","journal-title":"Curr Opin Obstet Gynecol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0000000000006161","article-title":"Prescribing trends in glucagon-like peptide-1 medications among pregnant and postpartum persons","volume":"147","author":"Lessard C","year":"2026","unstructured":"Lessard C, Cary C, In A, et al.. Prescribing trends in glucagon-like peptide-1 medications among pregnant and postpartum persons. Obstet Gynecol. 2026, 147:290-2. 10.1097\/AOG.0000000000006161","journal-title":"Obstet Gynecol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaf288","article-title":"Preexisting diabetes and pregnancy: an Endocrine Society and European Society of Endocrinology joint clinical practice guideline","volume":"110","author":"Wyckoff JA","year":"2025","unstructured":"Wyckoff JA, Lapolla A, Asias-Dinh BD, et al.. Preexisting diabetes and pregnancy: an Endocrine Society and European Society of Endocrinology joint clinical practice guideline. J Clin Endocrinol Metab. 2025, 110:2405-52. 10.1210\/clinem\/dgaf288","journal-title":"J Clin Endocrinol Metab"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2024.08.024","article-title":"Glucagon-like peptide-1 receptor agonist use in pregnancy: a review","volume":"232","author":"Drummond RF","year":"2025","unstructured":"Drummond RF, Seif KE, Reece EA. Glucagon-like peptide-1 receptor agonist use in pregnancy: a review. Am J Obstet Gynecol. 2025, 232:17-25. 10.1016\/j.ajog.2024.08.024","journal-title":"Am J Obstet Gynecol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.3070","article-title":"Glucagon-like peptide-1 receptor agonists in type 2 diabetes treatment: are they all the same?","volume":"35","author":"Gentilella R","year":"2019","unstructured":"Gentilella R, Pechtner V, Corcos A, Consoli A. Glucagon-like peptide-1 receptor agonists in type 2 diabetes treatment: are they all the same?. Diabetes Metab Res Rev. 2019, 35:3070. 10.1002\/dmrr.3070","journal-title":"Diabetes Metab Res Rev"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S506957","article-title":"A comprehensive review on the pharmacokinetics and drug-drug interactions of approved GLP-1 receptor agonists and a dual GLP-1\/GIP receptor agonist","volume":"19","author":"Min JS","year":"2025","unstructured":"Min JS, Jo SJ, Lee S, Kim DY, Kim DH, Lee CB, Bae SK. A comprehensive review on the pharmacokinetics and drug-drug interactions of approved GLP-1 receptor agonists and a dual GLP-1\/GIP receptor agonist. Drug Des Devel Ther. 2025, 19:3509-37. 10.2147\/DDDT.S506957","journal-title":"Drug Des Devel Ther"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/dom.16437","article-title":"Glucagon-like peptide 1 (GLP-1) receptor agonists' use during pregnancy: safety data from regulatory clinical trials","volume":"27","author":"Parker CH","year":"2025","unstructured":"Parker CH, Slattery C, Brennan DJ, le Roux CW. Glucagon-like peptide 1 (GLP-1) receptor agonists' use during pregnancy: safety data from regulatory clinical trials. Diabetes Obes Metab. 2025, 27:4102-8. 10.1111\/dom.16437","journal-title":"Diabetes Obes Metab"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-018-0668-z","article-title":"Pharmacokinetics and clinical implications of semaglutide: a new glucagon-like peptide (GLP)-1 receptor agonist","volume":"57","author":"Hall S","year":"2018","unstructured":"Hall S, Isaacs D, Clements JN. Pharmacokinetics and clinical implications of semaglutide: a new glucagon-like peptide (GLP)-1 receptor agonist. Clin Pharmacokinet. 2018, 57:1529-38. 10.1007\/s40262-018-0668-z","journal-title":"Clin Pharmacokinet"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/dom.70452","article-title":"Efficacy of liraglutide on metabolic and reproductive outcomes in women with polycystic ovary syndrome: a systematic review and meta-analysis","volume":"28","author":"Lu YT","year":"2026","unstructured":"Lu YT, Chang PH, Chen HJ, et al.. Efficacy of liraglutide on metabolic and reproductive outcomes in women with polycystic ovary syndrome: a systematic review and meta-analysis. Diabetes Obes Metab. 2026, 28:2523-35. 10.1111\/dom.70452","journal-title":"Diabetes Obes Metab"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1093\/humupd\/dmz019","article-title":"The role of glucagon-like peptide-1 in reproduction: from physiology to therapeutic perspective","volume":"25","author":"Jensterle M","year":"2019","unstructured":"Jensterle M, Janez A, Fliers E, DeVries JH, Vrtacnik-Bokal E, Siegelaar SE. The role of glucagon-like peptide-1 in reproduction: from physiology to therapeutic perspective. Hum Reprod Update. 2019, 25:504-17. 10.1093\/humupd\/dmz019","journal-title":"Hum Reprod Update"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2025.178459","article-title":"GLP-1RA partially alleviates obesity-induced reproductive dysfunction driven by the interplay mechanisms of inflammation and metabolic dysregulation via the SIRT-associated pathway","volume":"1011","author":"Matiki TW","year":"2026","unstructured":"Matiki TW, Ul Haq Shah MZ, Yin L, et al.. GLP-1RA partially alleviates obesity-induced reproductive dysfunction driven by the interplay mechanisms of inflammation and metabolic dysregulation via the SIRT-associated pathway. Eur J Pharmacol. 2026, 1011:178459. 10.1016\/j.ejphar.2025.178459","journal-title":"Eur J Pharmacol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa285","article-title":"Obesity, polycystic ovary syndrome, and infertility: a new avenue for GLP-1 receptor agonists","volume":"105","author":"Cena H","year":"2020","unstructured":"Cena H, Chiovato L, Nappi RE. Obesity, polycystic ovary syndrome, and infertility: a new avenue for GLP-1 receptor agonists. J Clin Endocrinol Metab. 2020, 105:2695-709. 10.1210\/clinem\/dgaa285","journal-title":"J Clin Endocrinol Metab"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1186\/s12902-023-01500-5","article-title":"Effects of GLP1RAs on pregnancy rate and menstrual cyclicity in women with polycystic ovary syndrome: a meta-analysis and systematic review","volume":"23","author":"Zhou L","year":"2023","unstructured":"Zhou L, Qu H, Yang L, Shou L. Effects of GLP1RAs on pregnancy rate and menstrual cyclicity in women with polycystic ovary syndrome: a meta-analysis and systematic review. BMC Endocr Disord. 2023, 23:245. 10.1186\/s12902-023-01500-5","journal-title":"BMC Endocr Disord"},{"key":"ref14","unstructured":"OZEMPIC (semaglutide) injection. (2026). Accessed. June 7, 2026: http:\/\/OZEMPIC (semaglutide) injection - accessdata.fda.gov."},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-023-01392-3","article-title":"Drug-drug interactions between glucagon-like peptide 1 receptor agonists and oral medications: a systematic review","volume":"47","author":"Calvarysky B","year":"2024","unstructured":"Calvarysky B, Dotan I, Shepshelovich D, Leader A, Cohen TD. Drug-drug interactions between glucagon-like peptide 1 receptor agonists and oral medications: a systematic review. Drug Saf. 2024, 47:439-51. 10.1007\/s40264-023-01392-3","journal-title":"Drug Saf"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.japh.2023.10.037","article-title":"The impact of tirzepatide and glucagon-like peptide 1 receptor agonists on oral hormonal contraception","volume":"64","author":"Skelley JW","year":"2024","unstructured":"Skelley JW, Swearengin K, York AL, Glover LH. The impact of tirzepatide and glucagon-like peptide 1 receptor agonists on oral hormonal contraception. J Am Pharm Assoc (2003). 2024, 64:204-211.e4. 10.1016\/j.japh.2023.10.037","journal-title":"J Am Pharm Assoc (2003)"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1002\/phar.70007","article-title":"GLP-1RA-induced delays in gastrointestinal motility: predicted effects on coadministered drug absorption by PBPK analysis","volume":"45","author":"Hooper L","year":"2025","unstructured":"Hooper L, Liu S, Pai MP. GLP-1RA-induced delays in gastrointestinal motility: predicted effects on coadministered drug absorption by PBPK analysis. Pharmacotherapy. 2025, 45:211-9. 10.1002\/phar.70007","journal-title":"Pharmacotherapy"},{"key":"ref18","unstructured":"Food and Drug Administration. WEGOVY. (2026). Accessed: June 7, 2026: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2026\/215256s033lbl.pdf."},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1215356","article-title":"Effects of GLP-1 agonists and SGLT2 inhibitors during pregnancy and lactation on offspring outcomes: a systematic review of the evidence","volume":"14","author":"Muller DR","year":"2023","unstructured":"Muller DR, Stenvers DJ, Malekzadeh A, Holleman F, Painter RC, Siegelaar SE. Effects of GLP-1 agonists and SGLT2 inhibitors during pregnancy and lactation on offspring outcomes: a systematic review of the evidence. Front Endocrinol (Lausanne). 2023, 14:1215356. 10.3389\/fendo.2023.1215356","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1111\/dom.70699","article-title":"Safety of GLP-1 and dual GLP-1\/GIP receptor agonists in preconception, pregnancy, and lactation: a systematic review of maternal, fetal, and neonatal outcomes","volume":"28","author":"Ozbek L","year":"2026","unstructured":"Ozbek L, Shah E, Al-Shiab R, et al.. Safety of GLP-1 and dual GLP-1\/GIP receptor agonists in preconception, pregnancy, and lactation: a systematic review of maternal, fetal, and neonatal outcomes. Diabetes Obes Metab. 2026, 28:4503-28. 10.1111\/dom.70699","journal-title":"Diabetes Obes Metab"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejogrb.2025.114836","article-title":"Impact of semaglutide exposure on fetal and neonatal outcomes in pregnant women: a systematic review","volume":"317","author":"Mandal L","year":"2026","unstructured":"Mandal L, Andersen LU, Luef BM, Tanvig MH, Vinter CA. Impact of semaglutide exposure on fetal and neonatal outcomes in pregnant women: a systematic review. Eur J Obstet Gynecol Reprod Biol. 2026, 317:114836. 10.1016\/j.ejogrb.2025.114836","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.2337\/dc26-S015","article-title":"Management of diabetes in pregnancy: standards of care in diabetes-2026","volume":"49","year":"2026","unstructured":"Management of diabetes in pregnancy. standards of care in diabetes-2026. Diabetes Care. 2026, 49:321-38. 10.2337\/dc26-S015","journal-title":"Diabetes Care"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0000000000006325","article-title":"Gestational weight gain and pregnancy outcomes after semaglutide exposure","author":"Yu Y","year":"2026","unstructured":"Yu Y, Li X, Groth SW, et al.. Gestational weight gain and pregnancy outcomes after semaglutide exposure. Obstet Gynecol. 2026, 10.1097\/AOG.0000000000006325","journal-title":"Obstet Gynecol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2026.2888","article-title":"Prepregnancy care and counseling: a review","volume":"335","author":"Cooper KM","year":"2026","unstructured":"Cooper KM, Szymanski LM, David PS, Allen SV, Breitkopf DM. Prepregnancy care and counseling: a review. JAMA. 2026, 335:1706-16. 10.1001\/jama.2026.2888","journal-title":"JAMA"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2025.20951","article-title":"Gestational weight gain and pregnancy outcomes after GLP-1 receptor agonist discontinuation","volume":"334","author":"Maya J","year":"2025","unstructured":"Maya J, Pant D, Fu Y, et al.. Gestational weight gain and pregnancy outcomes after GLP-1 receptor agonist discontinuation. JAMA. 2025, 334:2186-96. 10.1001\/jama.2025.20951","journal-title":"JAMA"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0000000000005995","article-title":"Gestational weight gain and hypertensive disorders of pregnancy with prepregnancy and early pregnancy glucagon-like peptide-1 receptor agonist exposure","volume":"147","author":"Pondugula N","year":"2026","unstructured":"Pondugula N, Culhane JF, Lundsberg LS, Partridge C, Merriam AA. Gestational weight gain and hypertensive disorders of pregnancy with prepregnancy and early pregnancy glucagon-like peptide-1 receptor agonist exposure. Obstet Gynecol. 2026, 147:293-302. 10.1097\/AOG.0000000000005995","journal-title":"Obstet Gynecol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2025.20947","article-title":"Increasing postpartum use of GLP-1 receptor agonists","volume":"334","author":"Bliddal M","year":"2025","unstructured":"Bliddal M, Nohmie G, Damkier P, Potteg\u00e5rd A. Increasing postpartum use of GLP-1 receptor agonists. JAMA. 2025, 334:2227-9. 10.1001\/jama.2025.20947","journal-title":"JAMA"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2025.11.001","article-title":"Optimization of postpartum care for patients with and at risk for premature and long-term cardiovascular disease: 2026 ACC expert consensus decision pathway: a report of the American College of Cardiology solution set Oversight Committee","author":"Lindley KJ","year":"2026","unstructured":"Lindley KJ, Bello NA, Berlacher KL, et al.. Optimization of postpartum care for patients with and at risk for premature and long-term cardiovascular disease: 2026 ACC expert consensus decision pathway: a report of the American College of Cardiology solution set Oversight Committee. J Am Coll Cardiol. 2026, 10.1016\/j.jacc.2025.11.001","journal-title":"J Am Coll Cardiol"},{"key":"ref29","unstructured":"MOUNJARO. (2026). Accessed. June 7, 2026: https:\/\/pi.lilly.com\/ca\/mounjaro-ca-pm.pdf."},{"key":"ref30","unstructured":"ZEPBOUND. (2026). Accessed. June 7, 2026: https:\/\/pi.lilly.com\/us\/zepbound-uspi.pdf."}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/507835-glucagon-like-peptide-1-receptor-agonists-and-reproductive-health-a-narrative-review-for-obstetrician-gynecologists","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T19:19:05Z","timestamp":1782933545000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/507835-glucagon-like-peptide-1-receptor-agonists-and-reproductive-health-a-narrative-review-for-obstetrician-gynecologists"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":30,"URL":"https:\/\/doi.org\/10.7759\/cureus.111915","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7,1]]}}}